Treatments for Patients with Resipiratory Infections/STRIVE (COVID-19) - Clinical Trial
Email to Participate
mary.motta@duke.edu
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called ensitrelvir (the study drug) is an effective option when it is given along with the current standard treatment for COVID-19.
What is the Condition Being Studied?
COVID-19
Who Can Participate in the Study?
Adults ages 18+ who are hospitalized with COVID-19.
For more information about who can join this study, please contact the study team at mary.motta@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Get a random assignment (like a coin flip) to receive either the study drug or placebo (sterile saline solution) through an infusion into a vein (IV)
- Have blood draws
- Keep in touch with the study team for about 60 days after you get the study drug
Study Details
Full Title
A Multicenter, Adaptive, Randomized, Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections
Principal Investigator
Heart Surgeon
Protocol Number
IRB:
PRO00112310
NCT:
NCT05605093
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email mary.motta@duke.edu